<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530256</url>
  </required_header>
  <id_info>
    <org_study_id>ALD518-CLIN-010</org_study_id>
    <nct_id>NCT01530256</nct_id>
  </id_info>
  <brief_title>Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)</brief_title>
  <acronym>ALD518-010</acronym>
  <official_title>An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in Subjects With Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitaeris INC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitaeris INC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safe and tolerable, biologically active, and
      potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to
      respond to glucocorticosteroids, for further investigation in Part B.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was terminated in line with the endpoint committee charter.
  </why_stopped>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events, including infections and loss of engraftment</measure>
    <time_frame>Through Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute GVHD Response at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Includes calculation of both complete and partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse of underlying malignant disease</measure>
    <time_frame>Through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through Week 24</time_frame>
    <description>Measured at 100 days post-first infusion, 6 months post-infusion and time of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcomes</measure>
    <time_frame>Through Week 24</time_frame>
    <description>As measured by the FACT-BMT.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute GvHD</condition>
  <arm_group>
    <arm_group_label>ALD518</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD518</intervention_name>
    <description>160 mg IV q 4 weeks for 4 doses</description>
    <arm_group_label>ALD518</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD518</intervention_name>
    <description>320 mg IV q 4 weeks for 4 doses</description>
    <arm_group_label>ALD518</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD518</intervention_name>
    <description>640 mg IV q 4 weeks for 2 doses</description>
    <arm_group_label>ALD518</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glucocorticosteroid refractory acute GVHD Grade 2-4

          -  Prior corticosteroid therapy at &gt; 1.0mg/kg methylprednisolone or equivalent for
             minimum of 3 and maximum of 14 days

          -  Karnofsky Performance Satus Scale â‰¥ 50%

          -  Adequate laboratory testing at screening

        Exclusion Criteria:

          -  Subjects having Stage 1 skin acute GVHD

          -  Subjects with Stage 3 or 4 liver GVHD

          -  Prior EBV associated malignancy

          -  Prior or current Hepatitis B or C

          -  Prior or active tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier San Martin, MD FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Alder Biopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <disposition_first_submitted>June 23, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 23, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 25, 2014</disposition_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allograph</keyword>
  <keyword>steroid refractory</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

